Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
249.18
-7.34 (-2.86%)
Aug 11, 2026, 11:04 AM EDT - Market open

Jazz Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $280.95. The average 1-year stock price forecast is 12.75% higher than the current stock price, while the lowest is $196 (-21.34%) and the highest is $315 (+26.41%).

Price Target: $280.95 (+12.75%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$196$280.95$283.5$315
Change-21.34%+12.75%+13.77%+26.41%

Analyst Ratings

The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy9910101111
Buy567777
Hold221111
Sell001111
Strong Sell000000
Total161719192020

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Truist Financial
Truist Financial
Buy
Maintains
n/a
BuyMaintainsn/an/aAug 11, 2026
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$280$283
BuyReiterates$280$283+13.57%Aug 11, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$300
BuyReiterates$300+20.39%Aug 11, 2026
RBC Capital
RBC Capital
Buy
Maintains
$258$273
BuyMaintains$258$273+9.56%Aug 11, 2026
UBS
UBS
Buy
Reiterates
$315
BuyReiterates$315+26.41%Aug 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.71B
from 4.27B
Increased by 10.31%
Revenue Next Year
4.97B
from 4.71B
Increased by 5.65%
EPS This Year
25.03
from 8.38
Increased by 198.71%
EPS Next Year
25.77
from 25.03
Increased by 2.94%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.09B3.66B3.83B4.07B4.27B4.71B
Revenue Growth
30.91%18.26%4.78%6.12%4.88%10.31%
Gross Profit
2.88B3.39B3.55B3.76B3.91B4.24B
Gross Margin
92.97%92.70%92.59%92.36%91.67%90.12%
Operating Income
475.26M839.14M816.23M864.14M1.02B2.03B
Net Income
-329.67M-224.06M414.83M560.12M-356.15M974.60M
EPS
----8.3825.03
EPS Growth
-----59.90%198.71%
Forward PE
8.238.546.295.727.679.95
Free Cash Flow
-138.27M1.12B1.06B1.44B1.35B1.53B
No. Analysts
-----18
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.8B
Avg4.7B
Low4.5B

Revenue Growth

Revenue Growth202620272028
High
12.0%
Avg
10.3%
Low
5.0%

EPS Forecast

EPS202620272028
High27.29
Avg25.03
Low24.04

EPS Growth

EPS Growth202620272028
High
225.7%
Avg
198.7%
Low
186.9%